Abstract 3937
Background
Surgical resection is the only curative treatment for pancreatic cancer but is very invasive. It usually causes severe stress in patients and may cause pain and deterioration of quality of life (QOL). Patient-reported QOL data are essential for describing patient symptomatology and evaluating care to adequately manage symptoms. Here we evaluated changes in health-related QOL (HRQOL) and symptoms in pancreatic cancer patients after surgical intervention.
Methods
The institutional review board of our university approved this study (2012-1-403); patients provided written informed consent. A QOL questionnaire survey was administered preoperatively and at postoperative months 3, 6, and 12. We statistically evaluated the correlations between the Short Form 36 Health Survey version 2 (SF-36v2 Standard, Japanese), which measures HRQOL, and specific symptoms of hepatobiliary and pancreatic cancer, using data collected from 100 postoperative pancreatic cancer patients (subtotal stomach-preserving pancreatoduodenectomy (PD), 54 patients; distal pancreatectomy, 36 patients; total pancreatectomy (TP), 10 patients). Responses were analyzed by two-way ANOVA and Spearman’s correlation coefficient analysis; p < 0.05 was considered significant. All statistical analyses were performed using SPSS (ver. 21).
Results
QOL was lowest at 3 months postoperatively on many domains of the SF-36v2 and had gradually improved by 12 months postoperatively. At 3 months, physical functioning (PF) (p < 0.001) and role-physical (RP) (p < 0.01) were significantly reduced in PD and TP patients. Also, QOL deterioration on SF-36v2 domains was correlated with weight loss (PF, RP, vitality (VT), role-emotional (RE); p < 0.05), worse bowel control (PF, BP, VT, RE, mental health (MH); p < 0.01-0.05), indigestion (PF, RP, GH, VT, social functioning, RE, MH; p < 0.001-0.05), appetite loss (all domains; p < 0.001-0.01), fatigue (PF, RE, MH; p < 0.05), and inability to perform usual activities (all domains, p < 0.001).
Conclusions
QOL after pancreatectomy can be improved by nutrition management, treatment combinations for symptoms related to digestion and absorption, and treatment for subjective symptoms including fatigue.
Clinical trial identification
Editorial acknowledgement
Think Science KK.
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI Grant Number JP16K07140.
Disclosure
F. Motoi: Speaker Bureau / Expert testimony: Taiho Pharma, Mylan Japan, Daichi-Sankyo. M. Unno: Research grant / Funding (self): Taiho Pharma, Chugai; Research grant / Funding (institution): Taiho Pharma, Pfizer, Takeda, Chugai, Yakult, Asahi-Kasei. All other authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract